Surrozen's President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center